Biomarin Pharmaceutical (BSP:B1MR34) Institutional Ownership : 0.00% (As of May. 01, 2024)

View and export this data going back to 2020. Start your Free Trial

What is Biomarin Pharmaceutical Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Biomarin Pharmaceutical's institutional ownership is 0.00%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Biomarin Pharmaceutical's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Biomarin Pharmaceutical's Float Percentage Of Total Shares Outstanding is 0.00%.

Biomarin Pharmaceutical Institutional Ownership Historical Data

The historical data trend for Biomarin Pharmaceutical's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomarin Pharmaceutical Institutional Ownership Chart

Biomarin Pharmaceutical Historical Data

The historical data trend for Biomarin Pharmaceutical can be seen below:

	2021-05-31	2021-06-30	2021-07-31	2021-08-31	2021-09-30	2021-10-31	2021-11-30	2021-12-31	2022-01-31	2022-02-28
Institutional Ownership	0.06	0.06	0.06	0.06	0.06	0.08	0.08	0.08	0.03	0.03

Biomarin Pharmaceutical Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

Biomarin Pharmaceutical (BSP:B1MR34) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biomarin Pharmaceutical Inc (BSP:B1MR34) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

BMRN:USA 1BMRN:Italy BM8:Germany

Address

770 Lindaro Street, San Rafael, CA, USA, 94901

Website

http://www.bmrn.com

BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the U.S. in 2023.

Biomarin Pharmaceutical (BSP:B1MR34) Headlines

No Headlines